Abstract

Review Article

Fibrinolytic therapy with tPA failed because it was based on a flawed concept

Victor Gurewich*

Published: 16 June, 2020 | Volume 5 - Issue 2 | Pages: 131-135

Fibrinolytic therapy has become synonymous with tissue plasminogen activator (tPA) based on the belief that tPA alone was responsible for natural fibrinolysis. Although this assumption was belied from the outset by disappointing clinical results, it persisted, eventually causing fibrinolysis to be discredited and replaced by an endovascular procedure. Since time to reperfusion is the critical determinant of outcome, which in acute myocardial infarction (AMI) means within two hours, a time-consuming hospital procedure is ill-suited as first line treatment. For this purpose, fibrinolysis is more fitting. The assumption that tPA is responsible for fibrinolysis is contradicted by published findings. Instead, tPA ‘s function is limited to the initiation of fibrinolysis, which is continued by urokinase plasminogen activator (uPA) and that has the dominant effect. tPA and uPA gene deletion and clot lysis studies showed the activators have complementary functions, requiring both for a full effect at fibrin-specific doses. They are also synergistic in combination thereby requiring lower doses for efficacy. A clinical proof of concept study in 101 AMI patients who were treated with a 5 mg bolus of tPA followed by a 90 minute infusion of prouPA, the native form of uPA. A near doubling of the 24 h TIMI-3 infarct artery patency rate was obtained compared to that in the best of the tPA trials (GUSTO). In further contrast to tPA, there were no reocclusions and the mortality was only 1% [1]. A sequential combination of both activators, mimicking natural fibrinolysis, holds promise to significantly improve the efficacy and safety of therapeutic fibrinolysis.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001099 Cite this Article Read Full Article PDF

Keywords:

Endogenous fibrinolysis; tPA; uPA; Fibrinolytic therapy

References

  1. Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, et al. for the PATENT Study Group. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and t-PA enhancement of thrombolysis (PATENT) trial. J Am Coll Cardiol. 1995; 26:  374-379. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/7608437
  2. Kuhn TS. Revolutionary view of the history of science: The structure of scientific revolutions. The Physics Teacher. 1967; 172.
  3. Flameng W, Lesaffre E, Vanhaecke J. Determinants of infarct size in nonhuman primates. Bas Res Cardiol. 1990; 85: 392-403. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/2241769
  4. Brodie BR, Webb J, Cox DA for the EMERALD Investigators. Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2007; 99: Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/17560875
  5. DeLuca G, Ernst N, Zijlstra F, van 't Hof AW, Hoorntje JC, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2004; 43: 1363-1367. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/15093868
  6. Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2002; 89: 1248-1252. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/12031722
  7. Stone GW, Gersh BJ. Facilitated angioplasty: paradise lost. Lancet. 2006; 367: 543-546. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/16488779
  8. Husain SS, Lipinski B, Gurewich V. Rapid purification of high affinity plasminogen activator from human plasma by specific adsorption on fibrin-celite. Proc Nat Acad Sci (USA). 1981; 78: 4265-4269. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/6270665
  9. Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell’Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990; 336: 65-75. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/1975321
  10. ISIS-3 Third International Study of Infarct Survival Collaborative Group. ISIS3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992; 339: 65-71. Pubmed: https://pubmed.ncbi.nlm.nih.gov/1347801/
  11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Eng J Med. 1993; 329: 673-682. Pubmed: https://pubmed.ncbi.nlm.nih.gov/8204123
  12. Brophy JM, Joseph L. Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. JAMA. 1995; 273: 871-875. Pubmed: https://pubmed.ncbi.nlm.nih.gov/7869558/
  13. Chandler WL, Jascur ML, Henderson PJ. Measurement of different forms of tissue plasminogen activator in plasma. Clin Chem. 2000; 46: 38-46. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/10620570
  14. Baglin TP, Landown R, Frasson R, Huntington JA. Discovery and characterization of an antibody directed against exosite 1 of thrombin. J Thromb Haemos. 2016; 14: 137142. Pubmed: https://pubmed.ncbi.nlm.nih.gov/26469093
  15. Vaughan DE, Vautloutle E, Collen D. Urokinase binds to platelets through a specific saturable, low affinity mechanism. Fibrinolysis. 1990; 4: 141.
  16. Gurewich V, Johnstone M, Loza JP, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets: implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett. 1993; 318: 317-321. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/8440390
  17. Grau E, Moroz LA. Fibrinolytic activity of normal human blood monocytes. Thromb Res. 1989; 53: 145-162. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/2922705
  18. Vassalli JD, Baccino D, Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985; 100: 86-92. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/3880760
  19. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost. 1999; 82: 259-270. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/10605712
  20. Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost. 2015; 13: S98-S105. Pubmed: https://pubmed.ncbi.nlm.nih.gov/26149056
  21. Singh I, Burnand KG, Collins M, Luttun A, Collen D, et al. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation. 2003; 107: 869-875. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/12591758
  22. Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Romer J, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA. 1996; 93: 5899-5904. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/8650190
  23. Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem. 1982; 257: 2920-2925. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/7199525
  24. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost. 2003; 89: 409-419. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/12624622
  25. Pannell R, Black J, Gurewich V. The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest. 1988; 81: 853-859. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/2963831
  26. Collen D, Stassen JM, Stump DC, Verstraete M. Synergism of thrombolytic agents in vivo. Circulation. 1986; 74: 838-842. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/3093116
  27. Gurewich V, Pannell R. Synergism of tissue-type plasminogen activator (tPA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Haemost. 1987; 57: 372-78. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/3116707
  28. Voskuilen M, Vermond A, Veeneman GH, et al. Fibrinogen lysine residue Aα157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem. 1987; 262: 5944-5946. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/3106345
  29. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982; 257: 2912-2919. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/7199524
  30. Marder VJ, Sherry S. Thrombolytic therapy: current status. N Engl J Med. 1988; 318: 1512-1520. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/3285216
  31. Harpel PC, Chang TS, Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem. 1985; 260: 4432-4440. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/3156857
  32. Suenson E, Lützen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem. 1984; 140: 513-522. Pubmed: https://pubmed.ncbi.nlm.nih.gov/6233145
  33. Liu J, Gurewich V. Fragment E-2 from fibrin substantially enhances prourokinase-induced glu-plasminogen activation. A kinetic study using a plasminresistant mutant pro-urokinase (Ala-158-rpro-UK). Biochemistry. 1992; 31: 6311-6317. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/1385727
  34. Petersen LC. Kinetics of reciprocal pro-urokinase/plasminogen activation. Stimulation by a template formed by the urokinase receptor bound to poly (Dlysine). Eur J Biochem. 1997; 245: 316-323. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/9151959
  35. Liu J, Gurewich V. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest. 1991; 88: 2012-2017. Pubmed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC295789/
  36. Weaver WD, Hartmann JR, Anderson JL, Reddy PS, Sobolski JC, et al. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. J Am Coll Cardio. 1994; 241: 1242-1248. Pubmed: https://pubmed.ncbi.nlm.nih.gov/7930246/
  37. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993; 329: 1615-1622. Pubmed: https://pubmed.ncbi.nlm.nih.gov/8232430/

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More